Ravi K. Amaravadi

机构：Hospital of the University of Pennsylvania, University of Pennsylvania · ORCID：0000-0002-5768-2474

发表论文 592 篇 · 总被引 42099 次 · h-index 84

代表论文

• Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8+ T cells (2024 · Cancer Cell · 被引 112)
• Engineered extracellular vesicles with DR5 agonistic scFvs simultaneously target tumor and immunosuppressive stromal cells (2025 · Science Advances · 被引 24)
• Neoadjuvant-adjuvant pembrolizumab in clinical stage IIB/C melanoma. (2025 · Journal of Clinical Oncology · 被引 10)
• Divergent effects of acute and chronic PPT1 inhibition in melanoma (2024 · Autophagy · 被引 10)
• Tumor-Infiltrating Lymphocytes in Necrotic Tumors after Melanoma Neoadjuvant Anti–PD-1 Therapy Correlate with Pathologic Response and Recurrence-Free Survival (2024 · Clinical Cancer Research · 被引 10)
• Antigen-specific profiling identifies T-bet+ melanoma-specific CD8+ T cells associated with response to neoadjuvant PD-1 blockade (2025 · Cancer Cell · 被引 5)